EC Number |
Application |
Reference |
---|
4.1.1.90 | medicine |
in WKY rats receiving a vitamin K-deficient diet that results in a 40% decrease of prothrombin activity, compound N-ethyl-2-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)tetradecylamide is able to counteract the effects on vitamin K deficiency and results in the complete restoration of prothrombin activity |
747280 |
4.1.1.90 | medicine |
multiplexed single nucleotide polymorphism panel (interrogation of the CYP2C9 *2, *3, VKORC1 (-1639G3A), and GGCX (1181T3G) alleles simultaneously) can be successfully used in genotyping of patient blood samples, whereby results can be combined with other clinical parameters in an algorithm for warfarin dosing |
703270 |
4.1.1.90 | medicine |
single nucleotide polymorphism in the GGCX gene may affect the dose of warfarin and other vitamin K antagonists |
716953 |
4.1.1.90 | medicine |
six out of seven patients with Pseudoxanthoma Elasticum habor mutations in the GGCX gene (gamma-glutamyl carboxylase) |
699400 |
4.1.1.90 | medicine |
warfarin therapy |
699860 |
4.1.1.90 | synthesis |
development of expression vectors which enable expressing mammalian gamma-glutamyl carboxylase, vitamin K epoxide reductase complex, subunit 1, and/or PDIA2 along with human coagulation factor VII in Drosophila Schnieder S2 cells. Mammalian GGCX i indispensable to synthesize active factor VII while mammalian vitamin K epoxide reductase complex, subunit 1, and PDIA2 are not critical but supportive factors for S2 cells |
747630 |